Michael Zell, MD
Urology · Scottsdale, AZNPI 1760860704
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,238 of the $63,713 with a category attached, or 74.1%. Stryker accounts for 93.7% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $23,329, more than ten times the $779 reported in 2019. Among urology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $468.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$60K
- Boston Scientific$2K
- Coloplast$419
- Partner Therapeutics, Inc.$338
- Procept Biorobotics Corporation$252
- Axonics, Inc.$164
- plus $1K from 20 others
What the payments were for
- Consulting fees$47,23874%
- Travel & lodging$11,27318%
- Food & beverage$5,2028%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 45 | $59,725 |
| Boston Scientific | 28 | $1,768 |
| Coloplast | 16 | $419 |
| Partner Therapeutics, Inc. | 1 | $338 |
| Procept Biorobotics Corporation | 3 | $252 |
| Axonics, Inc. | 4 | $164 |
| Travere Therapeutics, Inc. | 1 | $109 |
| Urogen Pharma, Inc. | 1 | $104 |
| Astellas Pharma US Inc | 6 | $99 |
| AbbVie(2 entities) | 4 | $99 |
| Dentsply IH AB | 3 | $87 |
| Tolmar, Inc. | 4 | $81 |
| Lumenis, Inc | 1 | $73 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $71 |
| Antares Pharma, Inc. | 4 | $60 |
| Neotract Inc. | 1 | $49 |
| Photocure Inc | 2 | $34 |
| Olympus America Inc. | 2 | $29 |
| Convatec Inc. | 2 | $28 |
| Teleflex LLC | 1 | $20 |
| Palette Life Sciences, Inc. | 1 | $20 |
| Progenics Pharmaceuticals, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Calyxo, Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Halozyme Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- S3$49,996
- 1788$32,483
- SPY-PHI SYSTEM$13,645
- LithoVue$394
- Leukine$338
- GENERAL ERECTILE DYSFUNCTION$283
- 1688$259
- Lumenis Pulse 120H$223
- VIRTUE$141
- AQUABEAM SYSTEM$140
- REZUM$122
- FLEXIVA$118
- NA$116
- (815) Thiola$109
- Axonics$107
- JELMYTO$104
How this compares
$63,713 in reported general payments places this provider in the 95th percentile of 269 urology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 68 | $39,252 |
| Solifenacin Succinate | 223 | $8,950 |
| Tamsulosin Hcl | 406 | $4,834 |
| Testosterone | 21 | $4,524 |
| Potassium Citrate ErPotassium Citrate | 36 | $3,251 |
| Tadalafil | 14 | $2,878 |
| Methenamine Hippurate | 38 | $2,195 |
| Finasteride | 133 | $1,826 |
| Testosterone Cypionate | 52 | $1,068 |
| Oxybutynin Chloride ErOxybutynin Chloride | 21 | $665 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 169 | $469 |
| Ciprofloxacin Hcl | 33 | $128 |
| Oxycodone Hcl | 64 | $103 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $99 | $39,25268 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 269 urology providers in Arizona.
Other urology in Scottsdale
- Thayne LarsonScottsdale$48K
- Jackson CaboScottsdale$36K
- Mark TysonScottsdale$34K
- Anojan NavaratnamScottsdale$30K
- Bernard GburekScottsdale$27K
- Matthew SteinwayScottsdale$23K
- Kelli GrossScottsdale$21K
- James DaitchScottsdale$16K
- Daniel FrendlScottsdale$15K
- Mitchell HumphreysPhoenix$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.